To examine the effect of therapeutic targeting and inhibition of EN2 expression on the rate of prostate cancer cell growth, cell proliferation was monitored by a thymidine incorporation assay after 72 hours of siRNA treatment against En-2 in PC3 and LNCaP cells. The gene discussed is EN2; the disease is prostate carcinoma.